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Abstract
In 2003, we started autologous bone marrow cell  infusion (ABMi) therapy for treating liver
cirrhosis.  ABMi  therapy  uses  400  mL of  autologous  bone  marrow obtained  under  general
anesthesia and infused mononuclear cells from the peripheral vein. The clinical study expanded
and we treated liver cirrhosis induced by HCV and HBV infection and alcohol consumption. We
found that  the ABMi therapy was effective for  cirrhosis  patients  and now we are treating
patients  with  combined HIV and HCV infection and with  metabolic  syndrome-induced liver
cirrhosis. Currently, to substantiate our findings that liver cirrhosis can be successfully treated
by the ABMi therapy, we are conducting randomized multicenter clinical studies designated
"Advanced medical technology B" for HCV-related liver cirrhosis in Japan. On the basis of our
clinical study, we developed a proof-of-concept showing that infusion of bone marrow cells
(BMCs) improved liver fibrosis and sequentially activated proliferation of hepatic progenitor cells
and hepatocytes, further promoting restoration of liver functions. To treat patients with severe
forms of liver cirrhosis, we continued translational research to develop less invasive therapies
by using mesenchymal stem cells derived from bone marrow. We obtained a small quantity of
BMCs under local anesthesia and expanded them into mesenchymal stem cells that will then be
used for treating cirrhosis. In this review, we present our strategy to apply the results of our
laboratory research to clinical studies. Copyright © 2014, Mary Ann Liebert, Inc.
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